Por: MarketWatch Business January 18, 2023
(ticker: MRNA) said Tuesday its experimental messenger RNA-based RSV vaccine, known as mRNA-1345, was 83.7% effective at preventing less severe disease in adults aged 60 and above, and 82.4% effective at preventing more severe disease. The company only released topline results, and said it would submit the complete data for publication in a scientific journal. Direct comparisons with the (PFE) and (GSK) RSV vaccines’ earlier trials are... + full article
Ars Technica USA Science January 19, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 18, 2023 8:54 pm UTC Share this story Moderna's mRNA-based vaccine against RSV (respiratory syncytial (sin-SISH-uhl) virus) was effective at preventing disease in older adults, according to preliminary,... + más
Moderna Says Its RSV Vaccine Trial Was a Success. A Clash With Pfizer and GSK Looms. | MarketWatch
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
CNBC USA Health December 06, 2022
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
Fox Business USA Business November 02, 2022
Check out what's clicking on FoxBusiness.com GSK opened 2% higher in U.S. trading Wednesday but closed down 2%. Shares rose after the drugmaker reported financial results that beat Wall Street forecasts and announced the Food and Drug Administration had accepted a biologics... + más
GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch
ABC7 USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.The preliminary results buoy hope that after decades of failure and frustration, vaccines... + más
Pfizer Says Its Maternal RSV Vaccine Can Protect Newborns From Severe Illness | NBC 6 South Florida
ABC News USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.The preliminary results buoy hope that after decades of failure and frustration, against RSV may... + más
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
10 WBNS USA Health November 01, 2022
NEW YORK — shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals each fall. The preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be... + más
Strong RSV vaccine data lifts hopes after years of futility | ABC News
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |